Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature.
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by an abnormal function of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in the phagocytic cells, which results in an increased susceptibility to severe bacterial and fungal infections. We report on a 12-year-old boy with X-linked CGD who was successfully treated with allogeneic bone marrow transplantation from an HLA-identical sibling following a conditioning regimen consisting of busulphan (BU, 16 mg/kg) and cyclophosphamide (CY, 200 mg/kg). At >2 years from transplant, the boy is in excellent clinical and hematological condition with full chimerism. Our patient is the 24th case of CGD transplanted from an HLA-identical sibling. A review of the literature revealed that 20 of 24 CGD patients are alive and disease free 1-7 years after transplant. Most of these patients were conditioned with the BUCY combination, which should be considered the recommended regimen.
Del Giudice
I
I
Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Via Benevento 6, 00161 Rome, Italy.
Iori
A P
AP
Mengarelli
A
A
Testi
A M
AM
Romano
A
A
Cerretti
R
R
Macrì
F
F
Iacobini
M
M
Arcese
W
W
D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D002648:Child; D041321:Chromosomes, Human, X; D003520:Cyclophosphamide / Q000008:administration & dosage; D008040:Genetic Linkage; D006105:Granulomatous Disease, Chronic / Q000235:genetics / Q000628:therapy*; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D035781:Siblings; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D003520:Cyclophosphamide; D002066:Busulfan